Investors Investors

Stock Quote

Stock Quote

11:54 PM EDT on Apr 26

Press Releases

Press Releases

All Releases
May 14, 2019
Leading Radiopharmaceutical Company ROTOP to Develop and Commercialize Progenics’ PSMA-Targeted SPECT/CT Imaging Agent in Europe NEW YORK & DRESDEN, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines
May 09, 2019
AZEDRA ® (iobenguane I 131) U.S. Commercial Launch Advancing with 22 Treatment Requests from Patients Received and 12 Centers Throughout the U.S. are Ready to Treat Patients Phase 2 Trial of 1095 Initiated with Enrollment to Begin 2Q 2019 Phase 3 CONDOR Trial of PyL TM Enrolling Ahead of Schedule
May 07, 2019
No Shareholder Action Required at this Time NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX, “Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued
May 06, 2019
Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed No Shareholder Action Required at this Time NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”),
May 06, 2019
-Phase 2/3 OSPREY Data Demonstrates PyL’s High Specificity and Sensitivity in Detecting Prostate Cancer- -Data Generated Under PyL Research Access Program Supports Potential of PyL to Detect Disease in Biochemical Recurrent Patients, Including Those with Low PSA Scores, and Impact Clinical
May 02, 2019
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first
Apr 24, 2019
Data from a Prospectively Designed Independent Trial of 130 Patients showed that PyL upstaged and downstaged disease in 65.5% of patients NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and
Apr 03, 2019
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the 18
Apr 03, 2019
Results from Phase 2/3 OSPREY Trial of PyL in Prostate Cancer Selected for an Oral Presentation NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and
Mar 14, 2019
AZEDRA ® (iobenguane I 131) U.S. Commercial Launch – 14 Treatment Requests from Patients Have Been Received and Scheduling for those Patients is Underway; 8 Centers Throughout the U.S. are Ready to Treat Patients Advancing Lifecycle Initiatives for AZEDRA in Additional MIBG-Avid Tumor Indications
Mar 14, 2019
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has asserted
Mar 11, 2019
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety data from a pooled analysis of all available clinical trial
Mar 07, 2019
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that it will host a conference call and webcast to review fourth quarter
Feb 11, 2019
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that it has acquired the Somerset, NJ manufacturing facility for AZEDRA ®
Jan 03, 2019
Accelerates European Development of PSMA-Targeted Imaging Agent with Global Leader in Nuclear Medicine NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and
Jan 02, 2019
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced the appointment of Asha Das, M.D.
Dec 03, 2018
-Potential to Improve Early Detection and Transform the Treatment Landscape for Recurrent Prostate Cancer - NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting
Nov 19, 2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety and tolerability data from a pooled analysis of four
Nov 08, 2018
AZEDRA ® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA) AZEDRA U.S. Launch Progressing and AZEDRA Added to the NCCN Guidelines and Four CMS-Recognized Drug Compendia Phase 3 Study of PyL TM for the Detection of Biochemical Recurrence of Prostate Cancer to Begin by Year End
Nov 06, 2018
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that management will present at the following upcoming investor